H.C. Wainwright raises Ionis Pharmaceuticals’ price target to $130 following FDA approval of its RNA-targeted therapy Tryngolza.
H.C. Wainwright increased its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $130 from $125, maintaining a Buy rating. The adjustment follows the FDA’s approval of Tryngolza, an RNA-targeted therapy.
Ionis also announced the completion of enrollment in the first cohort of its Phase 3 REVEAL study for obudanersen (ION582), targeting Angelman syndrome. The trial enrolled 136 participants aged 2 to under 18, with topline results expected in the second half of 2027.
The company specializes in RNA-targeted medicines, developing treatments for rare, neurological, and cardiometabolic diseases using antisense oligonucleotide technologies.